Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague-Dawley Rats But Aflibercept Affects Serum and Urine Metabolic Profiles.

Forsgård RA, Marrachelli VG, Lindén J, Frias R, Collado MC, Korpela R, Monleon D, Spillmann T, Österlund P.

Transl Oncol. 2019 Aug;12(8):1122-1130. doi: 10.1016/j.tranon.2019.04.019. Epub 2019 Jun 6.

2.

Nutritional Counseling for Head and Neck Cancer Patients Undergoing (Chemo) Radiotherapy-A Prospective Randomized Trial.

Orell H, Schwab U, Saarilahti K, Österlund P, Ravasco P, Mäkitie A.

Front Nutr. 2019 Mar 18;6:22. doi: 10.3389/fnut.2019.00022. eCollection 2019.

3.

Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.

Winther SB, Liposits G, Skuladottir H, Hofsli E, Shah CH, Poulsen LØ, Ryg J, Osterlund P, Berglund Å, Qvortrup C, Glimelius B, Sorbye H, Pfeiffer P.

Lancet Gastroenterol Hepatol. 2019 May;4(5):376-388. doi: 10.1016/S2468-1253(19)30041-X. Epub 2019 Mar 7.

PMID:
30852136
4.

Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy.

Soveri LM, Lamminmäki A, Hänninen UA, Karhunen M, Bono P, Osterlund P.

Acta Oncol. 2019 Apr;58(4):398-406. doi: 10.1080/0284186X.2018.1556804. Epub 2019 Jan 14.

PMID:
30638100
5.

Efficient Inhibition of Avian and Seasonal Influenza A Viruses by a Virus-Specific Dicer-Substrate Small Interfering RNA Swarm in Human Monocyte-Derived Macrophages and Dendritic Cells.

Jiang M, Österlund P, Westenius V, Guo D, Poranen MM, Bamford DH, Julkunen I.

J Virol. 2019 Feb 5;93(4). pii: e01916-18. doi: 10.1128/JVI.01916-18. Print 2019 Feb 15.

6.

Histologically Verified Biliary Invasion was Associated with Impaired Liver Recurrence-Free Survival in Resected Colorectal Cancer Liver Metastases.

Reijonen P, Österlund P, Isoniemi H, Arola J, Nordin A.

Scand J Surg. 2019 Sep;108(3):201-209. doi: 10.1177/1457496918812237. Epub 2018 Nov 21.

PMID:
30461352
7.

Highly Pathogenic H5N1 Influenza A Virus Spreads Efficiently in Human Primary Monocyte-Derived Macrophages and Dendritic Cells.

Westenius V, Mäkelä SM, Julkunen I, Österlund P.

Front Immunol. 2018 Jul 17;9:1664. doi: 10.3389/fimmu.2018.01664. eCollection 2018.

8.

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3).

Ali AS, Grönberg M, Langer SW, Ladekarl M, Hjortland GO, Vestermark LW, Österlund P, Welin S, Grønbæk H, Knigge U, Sorbye H, Janson ET.

Med Oncol. 2018 Mar 6;35(4):47. doi: 10.1007/s12032-018-1103-x.

9.

Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer?

Hermunen K, Lantto E, Poussa T, Haglund C, Österlund P.

Acta Oncol. 2018 Jun;57(6):750-758. doi: 10.1080/0284186X.2018.1431400. Epub 2018 Feb 1.

PMID:
29388498
10.

Postoperative CEA is a better prognostic marker than CA19-9, hCGβ or TATI after resection of colorectal liver metastases.

Peltonen R, Österlund P, Lempinen M, Nordin A, Stenman UH, Isoniemi H.

Tumour Biol. 2018 Jan;40(1):1010428317752944. doi: 10.1177/1010428317752944.

PMID:
29378497
11.

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.

Ali AS, Grönberg M, Federspiel B, Scoazec JY, Hjortland GO, Grønbæk H, Ladekarl M, Langer SW, Welin S, Vestermark LW, Arola J, Österlund P, Knigge U, Sorbye H, Grimelius L, Janson ET.

PLoS One. 2017 Nov 7;12(11):e0187667. doi: 10.1371/journal.pone.0187667. eCollection 2017.

12.

Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer-A definite conclusion?

Ducreux M, Österlund P, Pignon JP.

Semin Oncol. 2017 Apr;44(2):129-131. doi: 10.1053/j.seminoncol.2017.07.002. Epub 2017 Jul 29. No abstract available.

PMID:
28923210
13.

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.

Winther SB, Österlund P, Berglund Å, Glimelius B, Qvortrup C, Sorbye H, Pfeiffer P; - on behalf of the Academy of Geriatric Cancer Research (AgeCare).

BMC Cancer. 2017 Aug 16;17(1):548. doi: 10.1186/s12885-017-3526-8.

14.

Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague-Dawley rats.

Forsgård RA, Marrachelli VG, Korpela K, Frias R, Collado MC, Korpela R, Monleon D, Spillmann T, Österlund P.

Cancer Chemother Pharmacol. 2017 Aug;80(2):317-332. doi: 10.1007/s00280-017-3364-z. Epub 2017 Jun 23.

15.

Ebolavirus protein VP24 interferes with innate immune responses by inhibiting interferon-λ1 gene expression.

He F, Melén K, Maljanen S, Lundberg R, Jiang M, Österlund P, Kakkola L, Julkunen I.

Virology. 2017 Sep;509:23-34. doi: 10.1016/j.virol.2017.06.002. Epub 2017 Jun 5.

16.

Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.

Galleberg RB, Knigge U, Tiensuu Janson E, Vestermark LW, Haugvik SP, Ladekarl M, Langer SW, Grønbæk H, Österlund P, Hjortland GO, Assmus J, Tang L, Perren A, Sorbye H.

Eur J Surg Oncol. 2017 Sep;43(9):1682-1689. doi: 10.1016/j.ejso.2017.04.010. Epub 2017 May 4.

PMID:
28522174
17.

Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.

Guren TK, Thomsen M, Kure EH, Sorbye H, Glimelius B, Pfeiffer P, Österlund P, Sigurdsson F, Lothe IMB, Dalsgaard AM, Skovlund E, Christoffersen T, Tveit KM.

Br J Cancer. 2017 May 9;116(10):1271-1278. doi: 10.1038/bjc.2017.93. Epub 2017 Apr 11.

18.

Cachexia at diagnosis is associated with poor survival in head and neck cancer patients.

Orell-Kotikangas H, Österlund P, Mäkitie O, Saarilahti K, Ravasco P, Schwab U, Mäkitie AA.

Acta Otolaryngol. 2017 Jul;137(7):778-785. doi: 10.1080/00016489.2016.1277263. Epub 2017 Jan 26.

PMID:
28125312
19.

Global Curriculum Edition 2016: European Society for Medical Oncology/American Society of Clinical Oncology Recommendations for Training in Medical Oncology.

Dittrich C, Kosty MP, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir NS, Lotz JP, Österlund P, Pavlidis N, Purkalne G.

J Clin Oncol. 2017 Jan 10;35(2):254-255. Epub 2016 Oct 31. Review. No abstract available.

PMID:
28056204
20.

EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.

Ålgars A, Sundström J, Lintunen M, Jokilehto T, Kytölä S, Kaare M, Vainionpää R, Orpana A, Österlund P, Ristimäki A, Carpen O, Ristamäki R.

Int J Cancer. 2017 Feb 15;140(4):922-929. doi: 10.1002/ijc.30507. Epub 2016 Nov 23.

21.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y.

ESMO Open. 2016 Sep 29;1(5):e000097. eCollection 2016. Review.

22.

The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe.

Pavlidis N, Alba E, Berardi R, Bergh J, El Saghir N, Jassem J, Kosty M, Lopez RI, Lotz JP, Österlund P, Purkalne G, Dittrich C.

ESMO Open. 2016 Jan 18;1(1):e000004. eCollection 2016. No abstract available.

23.

FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders.

Lehtonen JM, Forsström S, Bottani E, Viscomi C, Baris OR, Isoniemi H, Höckerstedt K, Österlund P, Hurme M, Jylhävä J, Leppä S, Markkula R, Heliö T, Mombelli G, Uusimaa J, Laaksonen R, Laaksovirta H, Auranen M, Zeviani M, Smeitink J, Wiesner RJ, Nakada K, Isohanni P, Suomalainen A.

Neurology. 2016 Nov 29;87(22):2290-2299. Epub 2016 Oct 28.

24.

Intestinal permeability to iohexol as an in vivo marker of chemotherapy-induced gastrointestinal toxicity in Sprague-Dawley rats.

Forsgård RA, Korpela R, Holma R, Lindén J, Frias R, Spillmann T, Österlund P.

Cancer Chemother Pharmacol. 2016 Oct;78(4):863-74. doi: 10.1007/s00280-016-3150-3. Epub 2016 Sep 2.

25.

[Multidisciplinary tailoring of therapy of metastatic colon cancer].

Österlund P, Isoniemi H, Scheinin T, Ristimäki A, Lantto E.

Duodecim. 2016;132(12):1177-84. Review. Finnish.

PMID:
27483635
26.

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G; ESMO/ASCO Global Curriculum Working Group.

Ann Oncol. 2016 Aug;27(8):1378-81. doi: 10.1093/annonc/mdw239. No abstract available.

27.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D.

Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5.

PMID:
27380959
28.

Cellular Mechanism for Impaired Hepatitis C Virus Clearance by Interferon Associated with IFNL3 Gene Polymorphisms Relates to Intrahepatic Interferon-λ Expression.

Ferraris P, Chandra PK, Panigrahi R, Aboulnasr F, Chava S, Kurt R, Pawlotsky JM, Wilkens L, Osterlund P, Hartmann R, Balart LA, Wu T, Dash S.

Am J Pathol. 2016 Apr;186(4):938-51. doi: 10.1016/j.ajpath.2015.11.027. Epub 2016 Feb 16.

29.

A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer.

Loupakis F, Stein A, Ychou M, Hermann F, Salud A, Österlund P.

Target Oncol. 2016 Jun;11(3):293-308. doi: 10.1007/s11523-015-0400-y. Review.

30.

Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study.

Haugvik SP, Janson ET, Österlund P, Langer SW, Falk RS, Labori KJ, Vestermark LW, Grønbæk H, Gladhaug IP, Sorbye H.

Ann Surg Oncol. 2016 May;23(5):1721-8. doi: 10.1245/s10434-015-5013-2. Epub 2015 Dec 17.

PMID:
26678407
31.

Middle East respiratory syndrome coronavirus shows poor replication but significant induction of antiviral responses in human monocyte-derived macrophages and dendritic cells.

Tynell J, Westenius V, Rönkkö E, Munster VJ, Melén K, Österlund P, Julkunen I.

J Gen Virol. 2016 Feb;97(2):344-55. doi: 10.1099/jgv.0.000351. Epub 2015 Nov 24.

32.

RIG-I Signaling Is Essential for Influenza B Virus-Induced Rapid Interferon Gene Expression.

Mäkelä SM, Österlund P, Westenius V, Latvala S, Diamond MS, Gale M Jr, Julkunen I.

J Virol. 2015 Dec;89(23):12014-25. doi: 10.1128/JVI.01576-15. Epub 2015 Sep 16.

33.

MAP kinase p38α regulates type III interferon (IFN-λ1) gene expression in human monocyte-derived dendritic cells in response to RNA stimulation.

Jiang M, Österlund P, Fagerlund R, Rios DN, Hoffmann A, Poranen MM, Bamford DH, Julkunen I.

J Leukoc Biol. 2015 Feb;97(2):307-20. doi: 10.1189/jlb.2A0114-059RR. Epub 2014 Dec 3.

PMID:
25473098
34.

Efficient replication and strong induction of innate immune responses by H9N2 avian influenza virus in human dendritic cells.

Westenius V, Mäkelä SM, Ziegler T, Julkunen I, Österlund P.

Virology. 2014 Dec;471-473:38-48. doi: 10.1016/j.virol.2014.10.002. Epub 2014 Oct 25.

35.

NRS-2002 for pre-treatment nutritional risk screening and nutritional status assessment in head and neck cancer patients.

Orell-Kotikangas H, Österlund P, Saarilahti K, Ravasco P, Schwab U, Mäkitie AA.

Support Care Cancer. 2015 Jun;23(6):1495-502. doi: 10.1007/s00520-014-2500-0. Epub 2014 Nov 5.

PMID:
25370893
36.

Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?

Soveri LM, Hermunen K, de Gramont A, Poussa T, Quinaux E, Bono P, André T, Österlund P.

Eur J Cancer. 2014 Nov;50(17):2966-74. doi: 10.1016/j.ejca.2014.08.017. Epub 2014 Sep 26.

PMID:
25266443
37.

A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection.

Osterlund P, Peltonen R, Alanko T, Bono P, Isoniemi H.

Onco Targets Ther. 2014 Jul 1;7:1177-84. doi: 10.2147/OTT.S63739. eCollection 2014.

38.

Deoxycholic acid induced changes in electrophysiological parameters and macromolecular permeability in murine small intestine with and without functional enteric nervous system plexuses.

Forsgård RA, Korpela R, Stenman LK, Osterlund P, Holma R.

Neurogastroenterol Motil. 2014 Aug;26(8):1179-87. doi: 10.1111/nmo.12383. Epub 2014 Jun 23.

PMID:
24954839
39.

Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy.

Ålgars A, Avoranta T, Österlund P, Lintunen M, Sundström J, Jokilehto T, Ristimäki A, Ristamäki R, Carpén O.

PLoS One. 2014 Jun 18;9(6):e99590. doi: 10.1371/journal.pone.0099590. eCollection 2014.

40.

Novel avian influenza A (H7N9) virus induces impaired interferon responses in human dendritic cells.

Arilahti V, Mäkelä SM, Tynell J, Julkunen I, Österlund P.

PLoS One. 2014 May 7;9(5):e96350. doi: 10.1371/journal.pone.0096350. eCollection 2014.

41.

Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.

Manceau G, Imbeaud S, Thiébaut R, Liébaert F, Fontaine K, Rousseau F, Génin B, Le Corre D, Didelot A, Vincent M, Bachet JB, Chibaudel B, Bouché O, Landi B, Bibeau F, Leroy K, Penault-Llorca F, Van Laethem JL, Demetter P, Tejpar S, Rossi S, Mosakhani N, Osterlund P, Ristamäki R, Sarhadi V, Knuutila S, Boige V, André T, Laurent-Puig P.

Clin Cancer Res. 2014 Jun 15;20(12):3338-47. doi: 10.1158/1078-0432.CCR-13-2750. Epub 2014 Apr 25.

42.

Helicobacter pylori and gastrointestinal symptoms in diagnostics and adjuvant chemotherapy of colorectal cancer.

Soveri LM, Osterlund P, Ruotsalainen T, Poussa T, Rautelin H, Bono P.

Oncol Lett. 2014 Feb;7(2):553-559. Epub 2013 Nov 29.

43.

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.

Kubicka S, Greil R, André T, Bennouna J, Sastre J, Van Cutsem E, von Moos R, Osterlund P, Reyes-Rivera I, Müller T, Makrutzki M, Arnold D; ML18147 study investigators including AIO, GERCOR, FFCD, UNICANCER GI, TTD, BGDO, GEMCAD, and AGMT groups.

Ann Oncol. 2013 Sep;24(9):2342-9. doi: 10.1093/annonc/mdt231. Epub 2013 Jul 12.

PMID:
23852309
44.

[Conservative treatment for inoperable malign intestinal obstruction].

Saarto T, Osterlund P, Lepistö A.

Duodecim. 2013;129(4):410-7. Review. Finnish.

PMID:
23484358
45.

CEA fluctuation during a single fluorouracil-based chemotherapy cycle for metastatic colorectal cancer.

Hermunen K, Haglund C, Osterlund P.

Anticancer Res. 2013 Jan;33(1):253-60.

PMID:
23267153
46.

Does preoperative radiotherapy with postoperative chemotherapy increase acute side-effects and postoperative complications of total mesorectal excision? Report of the randomized Finnish rectal cancer trial.

Salmenkylä S, Kouri M, Österlund P, Pukkala E, Luukkonen P, Hyöty M, Pääkkönen M, Mäkelä J, Mustonen H, Järvinen HJ; Finnish Rectal Cancer Trial Group.

Scand J Surg. 2012;101(4):275-82.

PMID:
23238504
47.

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators.

Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16.

PMID:
23168366
48.

MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.

Mosakhani N, Lahti L, Borze I, Karjalainen-Lindsberg ML, Sundström J, Ristamäki R, Osterlund P, Knuutila S, Sarhadi VK.

Cancer Genet. 2012 Nov;205(11):545-51. doi: 10.1016/j.cancergen.2012.08.003. Epub 2012 Oct 23.

PMID:
23098991
49.

Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer.

Holma R, Korpela R, Sairanen U, Blom M, Rautio M, Poussa T, Saxelin M, Osterlund P.

J Clin Gastroenterol. 2013 Jan;47(1):45-51. doi: 10.1097/MCG.0b013e3182680201.

PMID:
23090038
50.

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.

Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U.

Ann Oncol. 2013 Jan;24(1):152-60. doi: 10.1093/annonc/mds276. Epub 2012 Sep 11.

PMID:
22967994

Supplemental Content

Loading ...
Support Center